1. Stocks
  2. Concord Biotech Ltd.
  3. Swot
swot-logo

Concord Biotech Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Concord Biotech Ltd. has 12 Strengths, 9 Weaknesses, 0 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Add SWOT widget to your site/app

Benjamin Graham Value Screen

Consistent Highest Return Stocks over Five Years

Expensive Performers (DVM)

Relative Outperformance versus Industry over 1 Week

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Companies with Low Debt

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Stocks Outperforming their Industry Price Change in the Quarter

PEG greater than Industry PEG

High PE (PE > 40)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Declining Net Cash Flow : Companies not able to generate net cash

Fall in Quarterly Revenue and Net Profit (YoY)

Weak Momentum: Price below Short, Medium and Long Term Averages

Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)

Increasing Trend in Non-Core Income

Top Losers

MFs decreased their shareholding last quarter

Rising Delivery Percentage Compared to Prev Day

Expensive Performers (DVM)

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)